Mary Yang, PhD

From Computational Models to Clinical Solutions

Arkansas Researcher Bridges the Gap in Cancer and Disease Treatment

Dr. Mary Yang is a leader in bioinformatics and data science, spearheading research with significant real-world implications. She has greatly enhanced the state's research capacity and quality as the director of the Joint Bioinformatics Program between the University of Arkansas (UA) at Little Rock, her home institution, and the University of Arkansas for Medical Sciences (UAMS).

Dr. Yang's research focuses on genomics, particularly DNA and RNA data. Her efforts in developing computational models help deepen our understanding of complex human diseases, especially cancer. Dr. Yang's laboratory, supported by the NIH, FDA, and NSF, has received numerous accolades, including the IEEE Bioinformatics and Bioengineering Outstanding Achievement Awards and the NIH Fellows Award for Research Excellence.

The Challenge

Researching and treating complex diseases like cancer and cardiovascular disorders is challenging because many different factors influence these diseases. These factors include genetics, the cell's environment, and lifestyle choices. Each case is unique.

Recent advances in genomics and bioinformatics have helped scientists understand these diseases' genetic and molecular details. However, combining large amounts of genetic data with clinical information to improve treatments and develop new therapies is still very challenging. This task requires advanced tools like mass spectrometers, highly controlled environments, and collaboration across different fields of study. This is crucial for integrating genetic data with clinical insights to develop effective treatments.

Additionally, the interaction between genetic risks and environmental factors makes creating effective treatments even more complicated.

The Solution

To this end, Dr. Yang develops computational models that can sift through large amounts of data, including from single-cell analyses, to uncover hidden information, facilitating a move toward truly personalized medicine. Dr. Yang's study of individual cells is particularly crucial in tumor analysis, as it allows researchers to understand the diverse cellular environment of cancers, which can vary greatly even within the same tumor. This level of detail is critical to pinpointing how different cells within a tumor may respond to treatments, leading to more precise therapeutic strategies.

Arkansas Research Alliance

Dr. Yang's computational models enable her to identify key biomarkers predicting how patients react to treatments. Her use of artificial intelligence helps untangle the complex genetic factors behind disease progression and drug resistance, offering more targeted and effective treatment strategies. This approach deepens our understanding of diseases at a genetic level and paves the way for precision medicine, significantly improving treatment outcomes.

Next Steps

A crucial goal of Dr. Yang's work is translating genomic research into clinical practice and developing personalized treatments. The following steps will help to achieve this goal:

- Drug Development Partnerships: Collaborating with pharmaceutical researchers and experts would assist in translating genomic insights into practical drug development. Partnerships with drug development researchers could help create targeted therapies based on genetic understandings of diseases, leading to more effective treatments with fewer side effects.

- Collaboration with Clinical Researchers: Forming strong partnerships with clinical scientists ensures that genomic discoveries are applied correctly in developing treatment protocols. These collaborations help bridge the gap between research findings and their practical application in a clinical setting. Moreover, they enable rigorous testing and assessment of the safety and effectiveness of treatments derived from genomic predictions, confirming their viability for clinic use.

These steps can help bring Dr. Yang's groundbreaking genomic research into the clinical domain, where it can directly impact patient care. Her work promises to transform patient outcomes, particularly in managing complex diseases like cancer, marking a pivotal shift towards more personalized and effective healthcare solutions.

Contact

mqyang@ualr.edu